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Abstract. Heart rate variability reflects current functional state of organism, the activity of 
autonomic nervous system and individual’s adaptive reserves in response to changes in external 
or internal body functioning conditions. The aim of this study is to evaluate regulatory changes 
of autonomous cardiac function on systemic level (RR variability), arising during peloidotherapy 
procedure in persons of different age and gender. 
The results showed differences in men’s and women’s autonomic nervous system response 
to peloidotherapy procedure – statistically significant time characteristic changes of HRV in 
men’s group start to appear only during third stage of the procedure, when humoral mechanisms 
kick in; in women’s group changes of frequency characteristics and their significant differences 
starts to appear already at the start of the procedure. Usually autonomic regulation of heart rate 
of older people is reduced; however heart rate variability changes during peloidotherapy 
procedure were adequate. 
Keywords: peloidotherapy, heart rate variability, autonomic nervous system, frequency domain 
of heart rate variability. 
1. Introduction 
Autonomic nervous system maintains inner balance - metabolic rate, body temperature, the 
average breathing rate, arterial blood pressure, heart rate and so on. Increased activity of 
autonomic nervous system is usually observed during most of chronic diseases. Autonomic 
nervous system activity by itself does not cause disease, but rather represents a response to 
actual or expected illness. The impact on autonomic nervous system is one of the most 
significant actions in balneotherapy and peloidotherapy procedures in treatment of chronic 
diseases. Autonomic nervous system activity changes during treatment in health resorts – in 
some cases overall autonomic nervous system tension or just sympathetic activity is reduced. In 
other cases parasympathetic impulsion is activated or equilibrium between both is restored [1]. 
Mud procedure acts on the mechanical, thermal, osmotic, chemical and other receptors on 
the skin and causes complex reactions of human body. Biologically active substances are acting 
in the skin, and acts through humoral route. Almost all physiological systems are involved into 
the general reaction of human organism during peloidotherapy. Reaction type and intensity 
depends on the intensity of mud procedure - temperature of mud, area of application, duration of 
the procedure, as well as the reactivity of the organism, which is quite difficult to determine [2]. 
Peloidotherapy is strong thermal and biochemical stimulus that acts primarily on 
thermoregulatory system which is associated with metabolic rate, cardiovascular system, blood 
flow redistribution in the body, respiratory function [3].  
Heart rate (HR) is a systemic parameter, its changes over time can be easily monitored [4], 
[5]. Heart rate variability (HRV), as the autonomic nervous system status indicator varies with 
age [6], is influenced by gender [7]. HRV changes assessed as prognostic indicators of disease 
for patients with cardiovascular problems - coronary heart disease, heart failure, after acute 
myocardial infarction [8]. 
The aim of this study is to evaluate regulatory changes of autonomous cardiac function on 
systemic level (RR variability), arising during peloidotherapy procedure in persons of different 
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age and gender. 
2. Methods  
The research was carried out in the health care resort centre “Druskininkų gydykla”.  
Procedure – therapeutic peat mud bath (39 ?C) (peat from “Mašnyčios” peat bog mixed with 
medium mineralization (~10 g/l) sodium-potassium-calcium chloride mineral water “Sveikata” 
in 1:2 ratio).  
The 12-lead standard ECG was registered synchronously using computerized ECG analysis 
system “Kaunas-Load”. ECG was registered continuously during whole procedure – 20 minutes. 
Three segments of equal lengths for 5 minutes were assessed from ECG: the beginning of the 
procedure 1-5 min (1), the middle of the procedure 7-12 min (2) and the end of the procedure 
15-20 min (3). Rhythmograms of each stage were analyzed using computerized ECG 
registration and analysis system “Kaunas – Load”. Heart rate (HR), RR interval and heart rate 
variability (HRV) characteristics were analyzed using the standard Fourier transform: 




Heart rate variability can be assessed in the time and frequency domains. Measures in the 
time domain include the standard deviation of the NN interval (SDNN), i.e. the square root of 
variance. This indicator reflects the parasympathetic effects and is suitable for short RR intervals 
sequences calculation, because the increase of the sequence length increases other factors 
influence on heart rate control, as well as the sympathetic influence, especially when the heart 
rate frequency changes [9]. Other indicator calculated - the square root of the mean squared 
differences of successive NN intervals (RMSSD), which is used in the assessment of 
parasympathetic effects during physical exertion or medication taken [9]. It is generally accepted 
that under resting conditions HRV in the time domain mainly reflects respiratory sinus 
arrhythmia, which is mediated by parasympatic cardiovagal outflow. 
 
Fig. 1. Rhytmogram of women (age 56 years), registered continuously during peloidotherapy 
Heart rate range was divided into three frequency bands: very low frequency (VLF2) (from 
0.003 till 0.04 Hz), low frequency (LF2) (from 0.04 till 0.15 Hz) and high frequency (HF2) (from 
0.15 till 0.4 Hz) components. LF (LF1) and HF (HF1) relative value of each power component in 
proportion to the total power minus the VLF component has been also calculated. The 
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representation of LF1 and HF1 in n.u. emphasizes the controlled and balanced behaviour of the 
two branches of the autonomic nervous system [9]. As well, “alpha” – coefficient of direction in 
log-log spectrum power presentation was calculated, “alpha” shown in tables mean evaluation 
for all strip in all spectrum, “alpha VLF” – evaluation for VLF of spectrum, “alpha LF” – 
evaluation for LF and “alpha HF” – evaluation for HF of spectrum. Evaluations of alpha about  
0 – white noise, alpha = 1 – pink noise, partially regulated process and alpha = 2 – brown noise, 
strongly regulated process. 
 
Fig. 2. Spectrogram of women (age 56 years), registered continuously during peloidotherapy 
Statistical analysis of the data. Data obtained from Fourier analysis was processed using 
SPSS 17.0. Arithmetic mean and standard deviation of parameters were calculated. The 
normality of distribution of results was estimated using the Shapiro-Wilk test. The data differed 
significantly from normal distribution. Reliability of differences of two independent group 
parameters was determined by the nonparametric Mann-Whitney test for two independent 
samples. In order to determine the significance of the differences between examinations at the 
start, in the middle and at the end stages of peloidotherapy procedure, non-parametric Wilcoxon 
test for paired samples was used. The significance level was chosen at ? ? 0.05. 
The study was carried out with Kaunas Regional Biomedical Research Ethics Committee 
permission No. BE-2-50. 
3. Results 
36 volunteers (16 male and 20 female; age between 30 and 82 years, mean 59.2 ± 11.9) were 
included in this study. All subjects were with no history of diabetes or cardiac disease.  
Peloidotherapy procedures for all subjects were appointed to treat symptoms of 
musculoskeletal disorders (osteoarthritis, spondylosis and spondyloarthrosis). In order to 
investigate whether heart rate variability changes during peloidotherapy procedures are 
influenced by gender, subjects were divided into groups by gender. Group I A consisted of 16 
men, average age of 59.125 ± 12.42 and I B group consisted of 20 women with mean age of 
59.25 ± 11.74. The two groups did not differ by age. In order to investigate whether heart rate 
variability is influenced by age, subjects were divided into two groups according to age: II A 
group consisted of 20 subject’s ≤ 59 years (9 men and 11 women), II B group consisted of 16 
subjects aged > 59 years. In this group, there were 7 males and 9 females. 
By nonparametric Mann-Whitney test for two independent samples IA and IB groups 
differed significantly only in the third phase of the variability Coherence (Hz) (? ? 0.036), and 
according to age and other indicators of heart rate variability there were no differences. II A and 
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II B groups differed by a second phase of RMSSD (? ? 0.018), alpha LF (? ? 0.001), alpha  
(? ? 0.049) and the third stage alpha HF (? ? 0.046). According to other indicators of heart rate 
variability statistically significant differences were not observed. 
Statistically significant changes of parameters throughout the procedure were comparied 
using non-parametric Wilcoxon test for paired samples. 
Table 1. Men (I A gr.), HRV changes during peloidotherapy, ? ? 16.  
(**** - ? ? 0.05 during all stages, *** - ? ? 0.05 between 1 and 2 stage,  
** - ? ? 0.05 between 2 and 3 stage, * - ? ? 0.05 between 1 and 3 stage, NS – no significant difference) 
 Time of peloidotherapy 
? < 0.05 HRV 1-5 min (1 stage) 8-13 min (2 stage) 15-20 min (3 stage) 
 Mean ±SD Mean ±SD Mean ±SD 
Mean of RR (ms) 851.79 120.90 806.17 103.10 772.41 85.42 **** 
1/min 71.74 8.87 75.50 8.44 78.74 8.11 **** 
Time domain        
SDNN (ms) 43.29 20.87 39.38 16.19 32.18 14.45 **, * 
RMSSD (ms) 33.72 25.79 31.63 22.45 23.72 16.43 **, * 
Freq. domain HRV 
(without VLF 
component) 
       
HF1 power (%) 55.60 13.55 54.85 12.18 57.60 13.07 NS 
LF1 power (%) 44.40 13.55 45.15 12.18 42.40 13.07 NS 
LF1 + HF1 power (ms2) 1704.83 989.20 1678.05 963.82 1592.71 926.44 NS 
LF1 / HF1 ratio 0.94 0.58 0.87 0.45 0.85 0.49 NS 
Coherence of  
variability (%) 40.20 8.04 39.92 10.89 42.10 11.27 NS 
Coherence of  
variability (Hz) 0.063 0.03 0.054 0.01 0.079 0.09 NS 
Freq. domain HRV 
(with VLF component)        
VLF2 power (%) 26.80 7.08 27.56 7.48 26.51 7.22 NS 
LF2 power (%) 32.03 9.26 31.49 8.74 30.72 9.38 NS 
HF2 power (%) 41.18 12.44 40.95 10.52 42.75 12.43 NS 
VLF2 power (ms2) 595.12 256.96 544.66 181.24 524.10 234.77 NS 
LF2 power (ms2) 780.53 644.73 719.82 511.01 643.66 379.45 NS 
HF2 power (ms2) 945.27 534.29 1020.74 764.77 950.11 696.36 NS 
Total power (ms2) 2320.92 1184.67 2285.22 1193.50 2117.87 1093.23 NS 
Alpha VLF -0.54 0.15 -0.44 0.32 -0.46 0.31 NS 
Alpha LF -1.32 0.67 -1.01 0.67 -1.11 0.62 NS 
Alpha HF -0.28 0.76 -0.29 0.63 -0.21 0.68 NS 
Alpha -0.64 0.30 -0.63 0.27 -0.60 0.31 NS 
In evaluating heart rate variability of men during peloidotherapy procedure, we see that 
standard deviation of the NN interval (SDNN) and square root of the mean squared differences 
of successive NN intervals (RMSSD) changes at the end of the procedure (15-20 minute of the 
procedure) and statistically significantly (? ? 0.05) differs from rates at the first and at the 
second stages of the procedure. Other evaluated characteristics of heart rate variability have not 
changed significantly during the procedure. 
In Tables 1, 2, 3, 4 we observe statistically significant increase in heart rate and shortening of 
RR interval throughout the procedure in all groups. 
In women group (Table No. 2) we have not founded statistically significant time reading 
changes of standard deviation of the NN interval (SDNN) and square root of the mean squared 
differences of successive NN intervals (RMSSD), but statistically (? ? 0.05) significant heart 
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rate frequency characteristics changes were observed. At the second stage of the procedure 
(8-13 minute) the relative influence of the sympathetic nervous system and overall power (ms2) 
of low frequency (LF1) and high frequency (HF1) parameters increases, and remains at the 
similar levels until the very end of the procedure – there are no statistically significant 
differences between these indicators at the second and the third stages of the procedure.  
LF1 / HF1 ratio increases throughout the procedure and statistically significant differences 
become apparent after 15 minute of the procedure (frequency characteristics without VLF 
componente). 
Table 2. Women (I B gr.) HRV changes during peloidotherapy procedures. ? ? 20.  
(**** - ? ? 0.05 between all stages, *** - ? ? 0.05 between 1 and 2 stage,  
** - ? ? 0.05 between 2 and 3 stage, * - ? ? 0.05 between 1 and 3 stage, NS – no significant difference) 
 Time of peloidotherapy 
? < 0.05 HRV 1-5 min (1 stage) 8-13 min (2 stage) 15-20 min (3 stage) 
 Mean ±SD Mean ±SD Mean ±SD 
Mean RR 808.10 115.42 776.62 111.43 739.04 109.77 **** 
1/min 74.10 13.26 79.00 11.36 83.14 11.95 **** 
Time domain        
SDNN (ms) 39.99 14.50 39.71 13.19 35.98 16.02 NS 
RMSSD (ms) 30.57 18.07 32.14 21.39 28.18 22.08 NS 
Freq. domain HRV 
(without VLF 
component) 
       
HF1 power (%) 60.49 9.52 57.14 8.45 55.76 8.99 ***, * 
LF1 power (%) 39.51 9.52 42.86 8.45 44.24 8.99 ***, * 
LF1 + HF1 power (ms2) 1810.22 995.78 1553.48 918.24 1353.95 858.11 ***, * 
LF1 / HF1 ratio 0.71 0.29 0.79 0.28 0.86 0.31 * 
Coherence of variability 
(%) 37.40 10.02 39.81 8.90 44.84 8.32 **, * 
Coherence of variability 
(Hz) 0.107 0.12 0.054 0.02 0.067 0.11 **** 
Freq. domain HRV 
(with VLF component)        
VLF2 power (%) 25.92 6.34 28.80 7.40 28.89 7.72 ***, * 
LF2 power (%) 28.85 5.86 30.02 5.18 31.08 6.09 NS 
HF2 power (%) 45.23 9.87 41.18 8.97 40.03 9.08 ***, * 
VLF2 power (ms2) 592.09 247.40 554.59 150.66 467.53 143.16 **, * 
LF2 power (ms2) 697.12 337.36 652.66 351.01 590.04 364.21 * 
HF2 power (ms2) 1139.23 685.22 927.82 576.97 763.90 522.47 **** 
Total power (ms2) 2428.44 1102.78 2135.07 948.16 1821.47 902.85 **** 
Alpha VLF -0.54 0.25 -0.55 0.34 -0.50 0.18 NS 
Alpha LF -1.07 0.76 -1.32 0.91 -1.10 0.62 NS 
Alpha HF -0.47 0.48 -0.46 0.41 -0.29 0.37 **, * 
Alpha -0.57 0.23 -0.63 0.21 -0.64 0.23 *** 
Correlative coherence of variability (%) statistically significantly increases only at the end of 
the procedure and coherence of variability (Hz) initially statistically significantly decreases and 
then increases significantly, but does not recover – statistically significant differences were 
observed during all stages of the procedure.  
In evaluating frequency characteristics with VLF componente, overall impact of LF2 
component expressed as percentages values contribution to the total variability of HR remain 
unchanged, and HF2 decreases with the increase in the VLF2 percentage values. During the 
procedure all parameters of frequency characteristics, that are expressed as absolute values (ms2), 
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changes – total power (ms2), VLF2 power (ms2), LF2 power (ms2), HF2 power (ms2). The only 
difference is the rate of change (Table No. 2). 
The changes in parameters of heart rate variability of younger than 59 years old subjects 
(Table No. 3), we see, that SDNN decreases during all procedure, but differences start to appear 
only at the end of the procedure. In evaluating frequency characteristics without VLF 
componente, at the 8-13 minute (2 stage) of the procedure we observe growing influence of 
sympathetic nervous system (LF1 power %) and later throughout the procedure the influence of 
parasympathetic nervous system (HF1 power %) began to grow, so there is no difference 
between the sympathetic and parasympathetic NS activity at the start and the end of the 
procedure. Overall power of LF1 and HF1 parameters (ms2) decreases till the middle of the 
procedure and remains at the same levels till the end of the procedure – there are no statistically 
significant difference between these values at the second and third stages of the procedure.  
LF1 / HF1 ratio increases throughout the procedure, but there are no statistically significant 
differences.  
Table 3. Younger people (≤ 59 years) (II A gr.) HRV changes during peloidotherapy procedure. ? ? 20.  
(**** - ? ? 0.05 between all stages, *** - ? ? 0.05 between 1 and 2 stages, ** - ? ? 0.05 between  
2 and 3 stages, * - ? ? 0.05 between 1 and 3 stages, NS – no significant difference) 
 Time of peloidotherapy 
? < 0.05 HRV 1-5 min (1 stage) 8-13 min (2 stage) 15-20 min (3 stage) 
 Mean ±SD Mean ±SD Mean ±SD 
Mean RR 835.01 126.72 793.38 115.73 749.23 107.79 **** 
1/min 71.72 12.46 77.17 10.32 81.79 11.16 **** 
Time domain        
SDNN (ms) 40.68 19.35 36.82 14.29 33.34 14.50 * 
RMSSD (ms) 26.12 17.10 24.50 14.58 20.86 13.86 NS 
Freq. domain HRV 
(without VLF 
component) 
       
HF1 power (%) 56.09 11.11 53.28 10.59 54.53 10.85 *** 
LF1 power (%) 43.96 11.11 46.72 10.59 45.47 10.85 *** 
LF1 + HF1 power (ms2) 1685.47 967.55 1501.28 860.88 1287.10 593.88 ***, * 
LF1 / HF1 ratio 0.88 0.46 0.92 0.42 0.93 0.43 NS 
Coherence of 
variability (%) 40.00 9.04 42.01 9.20 45.52 8.73 **, * 
Coherence of 
variability (Hz) 0.11 0.12 0.053 0.01 0.045 0.01 **** 
Freq. domain HRV 
(with VLF component)        
VLF2 power (%) 27.66 5.69 29.62 5.38 29.59 5.65 NS 
LF2 power (%) 31.56 8.06 31.84 7.19 31.71 7.39 NS 
HF2 power (%) 40.76 9.69 38.55 8.67 38.71 9.49 NS 
VLF2 power (ms2) 625.61 294.23 581.16 196.35 523.22 198.66 **, * 
LF2 power (ms2) 765.06 593.99 696.82 469.33 598.78 337.86 * 
HF2 power (ms2) 937.17 502.55 829.02 470.68 688.32 323.56 **** 
Total power (ms2) 2327.85 1213.05 2107.00 998.76 1810.32 756.88 **** 
Alpha VLF -0.51 0.21 -0.48 0.27 -0.43 0.26 NS 
Alpha LF -1.33 0.63 -1.59 0.75 -1.25 0.57 *** 
Alpha HF -0.49 0.72 -0.47 0.62 -0.40 0.58 NS 
Alpha -0.67 0.23 -0.70 0.21 -0.69 0.25 NS 
Variability coherence (%) statistically significantly increases at the end of the procedure and 
differs from first and second stage values. Variability coherence (Hz) statistically significantly 
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decreases throughout the procedure. Components of VLF2, LF2 and HF2 (frequency 
characteristics with VLF componente) expressed as percentages does not change, but the power 
of VLF2 range expressed in absolute values decreases at the end of the procedure and differs not 
only between first and third stage of the procedure, but between second and third stage of the 
procedure also. Power in LF2 range changes more slowly, differences start to appear only 
between first and third stage of the procedure. Power in HF2 range and overall power decreases 
much faster and statistically significant differences can be seen between all stages of the 
procedure. Alpha LF decreases at the beginning of the procedure and returns to initial values 
later. 
Heart rate variability (SDNN) of older than 59 years (Table No. 4) test subjects during 
peloidotherapy procedure haven't changed statistically significantly. At the end of the procedure 
statistically significant increase of variability coherence (%), decrease of power of VLF2 and 
HF2 range expressed in absolute values (ms2) and faster overall power decrease observed already 
at the first stage of the procedure. Alpha HF at the end of the procedure increased statistically 
significantly and differed from indices calculated at the beginning and in the middle stages of 
the procedure. 
Table 4. Older people (> 59 years) (II B gr.) HRV changes during peloidotherapy procedure. ? ? 16.  
(**** - ? ? 0.05 between all stages, *** - ? ? 0.05 between 1 and 2 stages, ** - ? ? 0.05 between  
2 and 3 stages, * - ? ? 0.05 between 1 and 3 stages, NS – no significant difference) 
 Time of peloidotherapy 
? < 0.05 HRV 1-5 min (1 stage) 8-13 min (2 stage) 15-20 min (3 stage) 
 Mean ±SD Mean ±SD Mean ±SD 
Mean RR 818.16 110.05 785.22 99.36 759.67 91.85 **** 
1/min 74.72 10.13 77.79 10.34 80.42 9.96 **** 
Time domain        
SDNN (ms) 42.43 15.23 42.99 14.18 35.47 16.54 NS 
RMSSD (ms) 39.29 24.73 41.18 25.48 32.88 23.88 NS 
Freq. domain HRV 
(without VLF 
component) 
       
HF1 power (%) 61.14 11.88 59.68 8.70 59.14 10.65 NS 
LF1 power (%) 38.93 11.94 40.33 8.70 40.86 10.65 NS 
LF1 + HF1 power (ms2) 1860.77 1018.38 1743.29 1016.21 1676.26 1135.03 NS 
LF1 / HF1 ratio 0.72 0.45 0.72 0.24 0.76 0.33 NS 
Coherence of 
variability (%) 36.95 9.36 37.17 9.89 41.25 10.57 * 
Coherence of 
variability (Hz) 0.06 0.02 0.055 0.02 0.106 0.14 NS 
Freq. domain HRV 
(with VLF 
component) 
       
VLF2 power (%) 24.62 7.40 26.56 9.16 25.64 9.01 NS 
LF2 power (%) 28.64 6.92 29.21 6.49 29.93 8.01 NS 
HF2 power (%) 46.74 12.16 44.23 9.93 44.43 11.39 NS 
VLF2 power (ms2) 553.22 175.50 511.45 99.72 454.48 173.74 * 
LF2 power (ms2) 695.60 337.94 664.62 374.49 632.73 410.41 NS 
HF2 power (ms2) 1197.84 736.43 1144.24 819.85 1044.59 802.13 * 
Total power (ms2) 2446.66 1038.50 2320.31 1134.04 2131.80 1221.82 ***, * 
Alpha VLF -0.57 0.21 -0.53 0.41 -0.54 0.21 NS 
Alpha LF -1.00 0.81 -0.67 0.56 -0.91 0.61 NS 
Alpha HF -0.26 0.46 -0.27 0.35 -0.08 0.39 **, * 
Alpha -0.51 0.28 -0.54 0.24 -0.53 0.27 NS 
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4. Discussion of the results 
Volume of the procedure, duration, mud temperature and chemical composition was the 
same for all subjects. During peloidotherapy procedure organism functions in unusual, similar to 
weightless state, conditions. When lying in a mud bath, a large amount of hot mud is pressing on 
the surface of the body, mechanically and chemically irritating skin receptors, changing blood 
circulation and heat exchange conditions [3]. Peloidotherapy causes intense functional changes 
in the body, and the adaptive organism response depends on the individual body reactivity and 
adaptive reserves. There are three body reactions to peloidotherapy procedures: the first two – 
reflexive and neurochemical take place during the procedure, and the third, the impact phase, 
lasts 2-24 hours after the procedure [2]. During first phase skin receptors are irritated and 
external energy is transformed into neural excitation pulses that spread to the CNS and cause 
complex changes in its function. At the second phase biologically active histamine and 
acetylcholine type substances are formed in the skin, which circulating in blood affect synapses 
and exposed sites of nerve endings, causing stimulation of all nervous system [2].  
Heart rate variability reflects cardiac rhythm management features, autonomic nervous 
system activity changes and changes of heart rate can be used to assess the functional status of 
organism and the ability to adapt to changing environmental conditions [11].  
Adequate body's regulatory systems reaction, mobilization of central circulatory system and 
training effect of peloidotherapy procedures represents a moderate increase of sympathetic 
nervous system activity at the beginning of treatment and the emerging increase of 
parasympathetic nervous system activity, heart rate variability and exercise tolerance during the 
treatment. Quantitative criteria of disadaptation is considered to be LF1 > 50 %, HF1 < 30 %,  
LF1 / HF1 > 2.5 [13]. 
Studies of many authors shows, that heart rate variability is influenced by subjects gender [7] 
and age [15]. However we have not found any statistically significant differences between heart 
rate variability parameters of men and women in separate stages of the procedure, there were 
only one difference of variability coherence (Hz) in third stage of the procedure. The age groups 
differed by second stage RMSSD, alpha LF, alpha and third stage alpha HF. However, the study 
showed different dynamics of heart rate variability of individual groups during peloidotherapy 
procedure. 
Throughout the procedure, all subject groups demonstrated increase of heart rate (HR) and 
shortening of RR interval duration. 
In group I A (men group) (Table No.1) only time characteristic parameters changed. Changes 
of SDNN which represents overall variability were observed at the third stage of the procedure, 
i.e. at the end of it. And the decrease of RMSSD value, which represents heart rate variability, 
shows functional tension of regulatory system and domination of central regulatory mechanisms, 
and can be seen as an emerging state of compensated fatigue [11]. 
In women’s group (Table No. 2), statistically significant changes in the all frequency 
characteristic parameters, except LF2 power (%), could be seen. Speed of dynamics of these 
parameters also varies – statistically significant differences starts to show at the first half of the 
procedure – sympathetic influence increases and parasympathetic influence decreases. VLF2 
component includes many of periodic oscillations, including thermoregulation and impact of 
rennin - angiotensin concentrations fluctuations in blood [9], so the relative increase of very low 
frequency (VLF2) component contribution to the total spectrum reflects the humoral response, 
and the decreased high frequency (HF2) component levels shows muffled autonomic responses 
[16]. Increase of LF1 / HF1 ratio confirms increase of activity of sympathetic nervous system. 
Such a response could be partly assessed as a protective response, manifesting by activation of 
autonomic regulation circle [11]. Assessing the results, we think, that men have less expressed 
first (reflexive) peloidotherapy phase, which lasts until mid-procedure, i.e. approximately till 
10-13 minute of the procedure, and the reaction of organism is revealed only in third stage of the 
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procedure, with activation of humoral mechanisms. Women, unlike men, have more pronounced 
and shorter first reflexive phase and earlier starting of the second, neurochemical phase. 
Differences of investigated parameters become apparent in the first half of the procedure. 
Literature analysis of heart rate variability shows that overall variability decreases with age, 
high frequency oscillations also disappearing, i.e. parasympathetic activity, and responses to 
physical activity decline and become more complex [9]. Our data of heart energetic spectrum 
analysis shows, that older people (II B gr.) had 24.6 % humoral and 74.6 % reflective activity at 
the first stage of the procedure at higher relative parasympathetic (46.7 %) than sympathetic 
influence (28.6 %) ant it was not statistically significantly different from younger people 
(II A gr.) cardiac energy spectrum. When assessing the results, we see the increase in relative 
sympathetic nervous system activity among people less than 59 years age group (Table No. 3) at 
the start of the peloidotherapy procedure, and then the reaction is stabilizing and 
parasympathetic influence beginning to grow again. In II B group (Table No. 4) statistically 
significant changes in these parameters were not observed. During the peloidotherapy procedure 
in group II B statistically insignificant fluctuations of humoral activity, the relative increase of 
sympathetic activity and decrease of parasympathetic activity where observed. In group II A 
(Table No. 3) throughout the procedure the relative increase of humoral activity, relative 
parasympathetic activity decrease trend, although no statistically significant difference between 
these parameters were found (? ? 0.05). Levels of sympathetic activity remain stable. Total 
power (ms2) and power in HF2 range (ms2) values decreases during all the procedure, and power 
in very low frequency range (VLF2 power (ms2)) and power in low frequency range 
(LF2 power  ms2)) – only at the end of the procedure. In II B group these values are changing 
slower (VLF2 power (ms2), HF2 power (ms2), total power (ms2)), or does not change at all 
(LF2 power (ms2)). 
So, we did not found any significant elderly parasympathetic nervous system activity 
impairment, and heart rate variability parameters showed adequate changes in the nature of the 
adaptive response in the treatment group to effects of peloidotherapy. 
5. Conclusions  
Time characteristic parameters changes in group of men and changes of frequency 
characteristic parameters in women group have shown the differences in adaptive responses for 
different gender during peloidotherapy procedure. Women’s adaptive response was faster, more 
pronounced, and is similar to protective body reaction. Autonomic regulation of heart rate is 
reduced for older people, but the results revealed no significant changes in heart rate variability 
during peloidotherapy procedure. 
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